RCAN1
Calcipressin-1
Protein Summary
Inhibits calcineurin-dependent transcriptional responses by binding to the catalytic domain of calcineurin A (PubMed:12809556). Could play a role during central nervous system development (By similarity). The protein encoded by this gene interacts with calcineurin A and inhibits calcineurin-dependent signaling pathways, possibly affecting central nervous system development. This gene is located in the minimal candidate region for the Down syndrome phenotype, and is overexpressed in the brain of Down syndrome fetuses. Chronic overexpression of this gene may lead to neurofibrillary tangles such as those associated with Alzheimer disease. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Nov 2013]
- ENST00000313806
- ENSP00000320768
- ENSG00000159200
- ENST00000381132
- ENSP00000370524
- ENST00000399272
- ENSP00000382214
- ENST00000443408
- ENSP00000392438
- ENST00000482533
- ENSP00000419624
- ENST00000487990
- ENSP00000419252
- ENST00000620920
- ENSP00000477646
- ADAPT78
- CSP1
- DSC1
- DSCR1
- CSP1
- DSC1
- RCN1
- DSCR1
- MCIP1
- ADAPT78
Most Knowledge About | Knowledge Value
(0 to 1 scale) | ||
|---|---|---|---|
kinase | 0.9 | ||
transcription factor | 0.9 | ||
PubMedID | 0.89 | ||
transcription factor perturbation | 0.88 | ||
disease perturbation | 0.87 | ||
Protein Classes
IDG Development Level Summary
These are targets about which virtually nothing is known. They do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 435.79 (req: < 5)
Gene RIFs: 108 (req: <= 3)
Antibodies: 521 (req: <= 50)
These targets do not have known drug or small molecule activities
- AND - satisfy two or more of the following criteria:
Pubmed score: 435.79 (req: >= 5)
Gene RIFs: 108 (req: > 3)
Antibodies: 521 (req: > 50)
- OR - satisfy the following criterion:
Gene Ontology Terms: 10
Target has at least one ChEMBL compound with an activity cutoff of < 30 nM - AND - satisfies the preceding conditions
Active Ligand: 0
Target has at least one approved drug - AND - satisfies the preceding conditions
Active Drug: 0